Advertisement

Use of dydrogesterone in hormone replacement therapy

Published:September 28, 2009DOI:https://doi.org/10.1016/j.maturitas.2009.09.013

      Abstract

      According to the Women's Health Initiative (WHI) study, the most important risks during combined hormone replacement therapy (HRT) are breast cancer, stroke and venous thromboembolism. To date, combinations of estradiol with natural progesterone or its retroisomer dydrogesterone are the only combined HRT regimens for which large case–control or cohort studies show no increase in any of these three risks. Moreover, due to the neutral effect of dydrogesterone on the vascular and metabolic systems, the preventive effect of the estradiol component with respect to myocardial infarction and metabolic syndrome can be maintained if HRT is started early after the menopause. Although a study with the same design as the WHI has not been performed, these results appear to be plausible considering the positive experimental evidence, particularly in the context of breast cancer and cardiovascular risks/benefits. Combination with dydrogesterone avoids endometrial hyperproliferation, maintains the beneficial effects of estradiol (i.e. efficacy against climacteric symptoms and prevention of osteoporotic fractures) and minimizes the most important risks known to be associated with the progestogen components of HRT regimens.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cieraad D.
        • Conradt C.
        • Jesinger D.
        • Bakowski M.
        Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
        Arch Gynecol Obstet. 2006; 274: 74-80
        • Lees B.
        • Stevenson J.C.
        The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17beta and dydrogesterone.
        Osteoporosis Int. 2001; 12: 251-258
        • Ferenczy A.
        • Gelfand M.M.
        • van de Weijer P.H.M.
        • Rioux J.E.
        Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17β-estradiol combined with sequential 5–20 mg dydrogesterone.
        Climacteric. 2002; 5: 26-35
        • Van de Weijer P.H.M.
        • Scholten P.C.
        • van der Mooren M.J.
        • Barentsen R.
        • Kenemans P.
        Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
        Climacteric. 1999; 2: 101-109
      1. Chabbert-Buffet N, Fabre A, Rahy Z, et al. Prevention of estrogen-induced endometrial cancer in postmenopausal women: micronized progesterone may not be as potent as other progestins. Presented at the 8th European Congress on Menopause, London, May 20th, 2009, Session ‘Breaking News’ Maturitas in press;63(Suppl. 1).

        • Writing Group for the Women's Health Initiative Investigators
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women.
        JAMA. 2002; 288: 321-333
        • Manson J.E.
        • Hsia J.
        • Johnson K.C.
        • et al.
        Estrogen plus progestin and the risk of coronary heart disease.
        New Engl J Med. 2003; 349: 523-534
        • The Women's Health Initiative Steering Committee
        Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.
        JAMA. 2004; 291: 1701-1712
        • Chen W.Y.
        • Manson J.E.
        • Hankinson S.E.
        • et al.
        Unopposed estrogen therapy and the risk of invasive breast cancer.
        Arch Intern Med. 2006; 166: 1027-1032
        • Li C.I.
        • Malone K.E.
        • Porter P.L.
        • et al.
        Relationship between menopausal hormone therapy and risk of ductal, lobular and ductal–lobular breast carcinoma.
        Cancer Epidemiol Biomarkers Prev. 2008; 17: 43-50
        • Krämer E.
        • Seeger H.
        • Krämer B.
        • Wallwiener D.
        • Mueck A.O.
        The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells.
        Menopause. 2005; 12: 468-474
        • Seeger H.
        • Rakov V.
        • Mueck A.O.
        Dose dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
        Horm Metab Res. 2005; 37: 468-473
        • Krämer E.
        • Seeger H.
        • Krämer B.
        • Wallwiener D.
        • Mueck A.O.
        Characterization of the stimulatory effect of medroxyprogesterone acetate and chlormadinone acetate on growth factor treated normal human breast epithelial cells.
        J Steroid Biochem Mol Biol. 2006; 98: 174-178
        • Seeger H.
        • Wallwiener D.
        • Mueck A.O.
        Effects of estradiol and progestogens on TNF-alpha induced changes of biochemical markers for breast cancer growth and metastasis.
        Gynecol Endocrinology. 2008; 24: 576-579
        • Chetrite G.S.
        • Thole H.H.
        • Philippe J.C.
        • Pasqualini J.R.
        Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase activity.
        Anticancer Res. 2004; 24: 1433-1438
        • Franke H.R.
        • Vermes I.
        Differential effects of progestogens on breast cancer cell lines.
        Maturitas. 2003; 46: S55-S58
        • Fournier A.
        • Berrino F.
        • Clavel-Chapelon F.
        Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
        Breast Cancer Res Treat. 2008; 107: 103-111
        • Fournier A.
        • Fabre A.
        • Mesrine S.
        • Boutron-Ruault M.C.
        • Berrino F.
        • Clavel-Chapelon F.
        Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor defined invasive breast cancer.
        J Clin Oncol. 2008; 26: 1260-1268
        • Lyytinen H.
        • Pukkala E.
        • Ylikorkala O.
        Breast cancer risk in postmenopausal women using estradiol–progestogen therapy.
        Obstet Gynecol. 2009; 113: 65-73
        • Schneider C.
        • Jick S.S.
        • Meier C.R.
        Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
        Climacetric. 2009; ([Epub ahead of print]): 1-11
        • Mueck A.O.
        • Seeger H.
        The role of progestogens in breast cancer: experimental vs. clinical data.
        Menopausal Med. 2006; 14: 1-6
        • International Menopause Society (on behalf of the Board)
        IMS updated recommendations on postmenopausal hormone therapy.
        Climacteric. 2007; 10: 181-194
        • WHI Investigators
        Conjugated equine estrogens and coronary heart disease.
        Arch Intern Med. 2006; 166: 357-365
        • Sacket D.L.
        Evidence-based medicine: what it is and what it isn’t.
        BMJ. 1996; 312: 71-72
        • American Heart Association Science Advisory and Coordinating Committee
        Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.
        Circulation. 2007; 115: 1481-1501
        • de Kraker A.T.
        • Kenemans P.
        • Smolders R.G.
        • Kroeks M.V.
        • van der Mooren M.J.
        The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
        Maturitas. 2004; 49: 253-263
        • Stevenson J.C.
        • Rioux J.E.
        • Komer L.
        • Gelfand M.
        1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
        Climacteric. 2005; 8: 352-359
        • Gelfand M.M.
        • Fugere P.
        • Bissonnette F.
        • et al.
        Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology and bleeding.
        Menopause. 1997; 4: 10-18
        • Pornel B.
        • Chevallier O.
        • Netelenbos J.C.
        Oral 17β-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
        Menopause. 2002; 9: 171-178
        • Hänggi W.
        • Lippuner K.
        • Riesen W.
        • Jaeger P.
        • Birkhäuser M.
        Long term influence of different postmenopausal hormone replacement regimes on serum lipids and lipoprotein(a): a randomized study.
        Br J Obstet Gynaecol. 1997; 104: 708-717
        • Hellgren M.
        • Conard J.
        • Norris L.
        • Kluft C.
        Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
        Maturitas. 2009; 62: 287-293
        • Hoefler G.
        • Harnoncourt F.
        • Paschke E.
        • Mirtl W.
        • Pfeiffer K.H.
        • Kostner G.M.
        Lipoprotein Lp(a). A risk factor for myocardial infarction.
        Arteriosclerosis. 1988; 8: 398-401
        • Crook D.
        • Godsland I.F.
        • Hull J.
        • Stevenson J.C.
        Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up.
        Br J Obstet Gynaecol. 1997; 104: 298-304
        • Gaspard U.J.
        • Wery O.J.
        • Scheen A.J.
        • Jaminet C.
        • Lefebvre P.J.
        Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women.
        Climacteric. 1999; 2: 93-100
        • Godsland I.F.
        • Manassiev N.A.
        • Felton C.V.
        • et al.
        Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
        Clin Endocrinol. 2004; 60: 541-549
        • Dansuk R.
        • Unal O.
        • Karsidag Y.K.
        • Turan C.
        Evaluation of the effects of various gestogens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy.
        Gynecol Endocrinol. 2004; 20: 1-5
        • Fibrinogen Studies Collaboration
        Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality.
        JAMA. 2005; 294: 1799-1809
        • Van der Mooren M.J.
        • Demacker P.N.M.
        • Thomas C.M.G.
        • Rolland R.
        Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
        Eur J Obstet Gynecol Reprod Biol. 1992; 47: 153-160
        • Mijatovic V.
        • Kenemans P.
        • van der Mooren M.J.
        • et al.
        Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women.
        Fibrinolysis Proteolysis. 1999; 13: 177-183
        • Kannel W.B.
        Overview of hemostatic factors involved in atherosclerotic disease.
        Lipids. 2005; 40: 1215-1220
        • American Heart Association Scientific Statement
        Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for health professionals from the Centers for Disease Control (CDC) and prevention and the American Heart Association (AHA).
        Circulation. 2003; 107: 499-511
        • Kwok S.
        • Charlton-Menys V.
        • Pemberton P.
        • McElduff P.
        • Durrington P.N.
        Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
        Maturitas. 2006; 53: 439-446
        • van Baal W.M.
        • Kenemans P.
        • Emeis J.J.
        • et al.
        Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.
        Fertil Steril. 1999; 71: 663-670
        • Mijatovic V.
        • Kenemans P.
        • Netelenbos C.
        • et al.
        Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
        Fertil Steril. 1998; 69: 876-882
        • Chiantera V.
        • Sarti C.D.
        • Fornaro F.
        • et al.
        Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
        Menopause. 2003; 10: 286-291
        • Smolders R.G.
        • de Meer K.
        • Kenemans P.
        • Teerlink T.
        • Jakobs C.
        • van der Mooren M.J.
        Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.
        Eur J Obstet Gynecol Reprod Biol. 2004; 117: 55-59
        • Raghupathy R.
        • Al Mutawa E.
        • Makhseed M.
        • Azizieh F.
        • Szekeres-Bartho J.
        Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage.
        BJOG. 2005; 112: 1-6
        • Walch K.
        • Hefler L.
        • Nagele F.
        Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial.
        J Matern Fetal Neonatal Med. 2005; 18: 265-269
        • Mendelsohn M.E.
        • Karas R.H.
        The protective effects of estrogen on the cardiovascular system.
        N Engl J Med. 1999; 340: 1801-1811
        • Cid M.C.
        • Schnaper H.W.
        • Kleinman H.K.
        Estrogens and the vascular endothelium.
        Ann NY Acad Sci. 2002; 966: 143-157
        • Seeger H.
        • Mueck A.O.
        Effects of dydrogesterone on the vascular system.
        Gynecol Endocrinol. 2007; 23: 2-8
        • Anggard E.
        Nitric oxide: mediator, murderer, and medicine.
        Lancet. 1994; 343: 1199-1206
        • Simoncini T.
        • Caruso A.
        • Giretti M.S.
        • et al.
        Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells.
        Fertil Steril. 2006; 86: 1235-1242
        • Mueck A.O.
        • Seeger H.
        Effect of hormone therapy on blood pressure in normotensive and hypertensive postmenopausal women.
        Maturitas. 2004; 49: 189-203
        • van Ittersum F.J.
        • van Baal W.M.
        • Kenemans P.
        • et al.
        Ambulatory–not office–blood pressures decline during hormone replacement therapy in healthy postmenopausal women.
        Am J Hypertens. 1998; 11: 1147-1152
        • Kaya C.
        • Cengiz S.D.
        • Cengiz B.
        • Akgün G.
        The long-term effects of low-dose 17β-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized prospective study.
        Climacteric. 2006; 9: 437-445
        • Bourne T.
        • Hillard T.C.
        • Whitehead M.I.
        • Crook D.
        • Campbell S.
        Oestrogens, arterial status, and postmenopausal women.
        Lancet. 1990; 335: 1470-1471
        • Gambacciani M.
        • Monteleone P.
        • Vitale C.
        • et al.
        Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial.
        Maturitas. 2002; 43: 117-123
        • Luckas M.J.
        • Gleeve T.
        • Biljan M.M.
        • et al.
        The effect of progestogen on the carotid artery pulsatility index in postmenopausal women on oestrogen replacement therapy.
        Eur J Obstet Gynecol Reprod Biol. 1998; 76: 221-224
        • Kessel H.
        • Kamp O.
        • Kenemans P.
        • et al.
        Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.
        Am J Obstet Gynecol. 2001; 184: 910-916
        • Miller J.
        • Chan B.K.S.
        • Nelson H.D.
        Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2002; 136: 680-690
        • Canonico M.
        • Oger E.
        • Plu-Bureau G.
        • et al.
        Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER Study.
        Circulation. 2007; 115: 840-845
        • Prospective Studies Collaboration
        Age-specific relevance of usual blood pressure to vascular mortality. A meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • Vasan R.S.
        • Larson M.G.
        • Leip E.P.
        • et al.
        Impact of high-normal blood pressure on the risk of cardiovascular disease.
        N Engl J Med. 2001; 345: 1291-1297
        • Schneider C.
        • Jick S.S.
        • Meier C.R.
        Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.
        Climacteric. 2009; ([Epub ahead of print]): 1-9
        • American Heart Association Science Advisory and Coordinating Committee
        Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association Conference on scientific issues related to management.
        Circulation. 2004; 109: 551-556
        • Lobo R.A.
        Metabolic syndrome after menopause and the role of hormones.
        Maturitas. 2008; 60: 10-18